Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

| More on:
A happy couple looking at an iPad feeling great as they watch the Challenger share price rise

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It has been another busy week for Australia's top brokers. This has led to the release of a number of broker notes.

Three broker buy ratings that you might want to know more about are summarised below. Here's why brokers think these ASX shares are in the buy zone:

BHP Group Ltd (ASX: BHP)

According to a note out of Goldman Sachs, its analysts have retained their buy rating on this mining giant's shares with a slightly reduced price target of $49.20. Goldman Sachs has been running the rule over the mining sector ahead of the release of quarterly updates this month. It believes BHP will deliver a reasonably solid quarterly update. For example, the broker expects copper and metallurgical coal production to increase quarter on quarter. But the main reasons the broker is positive are BHP's attractive valuation, its optionality with a +US$20 billion copper pipeline and strong production growth, and its robust free cash flow generation. The BHP share price was trading at $44.35 on Friday.

Mesoblast Ltd (ASX: MSB)

A note out of Bell Potter reveals that its analysts have retained their speculative buy rating on this cellular medicines developer's shares with an increased price target of $1.40. Bell Potter points out that the FDA has informed Mesoblast that available clinical data from a Phase 3 study for children with steroid refractory acute graft versus host disease appears sufficient to support a resubmission of the Biological Licence Application for its Remestemcel product. It believes the timing of the correspondence is no coincidence. The broker highlights that there is refreshed leadership at the newly formed Office of Therapeutic Products at the FDA. In light of this, its analysts have renewed confidence for a prospective approval of Remestemcel later this year. It also feels that a first approval may represent a gateway to a series of label expansions in the ensuing period. The Mesoblast share price was fetching 86.5 cents at the end of the week.

Treasury Wine Estates Ltd (ASX: TWE)

Analysts at UBS have retained their buy rating on this wine giant's shares with an improved price target of $15.25. This follows confirmation that the Chinese Ministry of Commerce (MOFCOM) is removing tariffs from Australian wine imports into China. According to the note, UBS was pleased with the news and believes that Treasury Wine's shares now deserve to trade on higher earnings multiples. Especially given that this news increases its addressable market. Its analysts have also lifted their earnings estimates to reflect the news and higher margin assumptions for its premium wine. The Treasury Wine share price ended the week at $12.86.

Motley Fool contributor James Mickleboro has positions in Treasury Wine Estates. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group. The Motley Fool Australia has recommended Treasury Wine Estates. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

A man clenches his fists in excitement as gold coins fall from the sky.
Broker Notes

These ASX shares could rise 20% to 40%

Big returns could be on offer from these stocks according to analysts.

Read more »

Two parents and two children happily eat pizza in their kitchen as a top broker predicts a 46% upside for the Domino's share price
Broker Notes

Buy one, sell the other: Goldman's take on these 2 ASX retail shares

Despite high interest rates and inflation, ASX retail shares have been on a strong run.

Read more »

A male sharemarket analyst sits at his desk looking intently at his laptop with two other monitors next to him showing stock price movements
Broker Notes

Brokers name 3 ASX shares to buy now

Here's why brokers are feeling bullish about these three shares this week.

Read more »

Woman and man calculating a dividend yield.
Bank Shares

Is the Macquarie share price worth $200 after its FY25 update?

Here’s a top broker’s view on the global investment bank.

Read more »

Man holding out Australian dollar notes, symbolising dividends.
Broker Notes

How I'd invest $5,000 in ASX shares right now

Analysts think these buy-rated stocks could be great options for those funds.

Read more »

A female stockbroker reviews share price performance in her office with the city shown in the background through her windows
Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

Read more »

Miner looking at a tablet.
Broker Notes

Should you buy the dip on South32 shares?

Could the sell-off be a buying opportunity?

Read more »

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Broker Notes

Why did this top broker just downgrade DroneShield shares?

The broker believes its shares are fully valued at current levels.

Read more »